METHODS
 We performed a researcher-initiated, academically financed, double-blind, placebo controlled, parallel group, randomized trial with the histamine H2 antagonist famotidine in treatment resistant schizophrenia.  The subjects were all treatment resistant subjects who had a significant level of residual symptoms.  The subjects (N=30) were randomized to have either high-dose famotidine (100 mg twice daily, N=16) or placebo (N=14) orally, added to their normal treatment regimen for four weeks.  Before the first assessment there was a one-week placebo run-in. After the trial phase there was a one-week wash out before the last assessment.  The subjects were followed weekly with the Scale for the Assessment of Negative Symptoms (SANS) as well as Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression-scale (CGI).  This trial was registered at ClinicalTrials.gov (NCT00565175).
RESULTS
 All of the subjects in the intervention group showed significantly reduced symptomatology while the symptoms of those in the placebo group did not show any significant change.  In the intervention group the SANS score was reduced by 5.3 points while in the placebo group the SANS score was virtually unchanged (p=0.134).  PANSS Total score and the General sub-score as well as the CGI showed significantly (p<0.05) greater change in the intervention group than in the placebo group.  It is noteworthy that the reduction of symptoms started from the baseline measurement and was consistent all the way to the endpoint.
CONCLUSIONS
 This is the first placebo controlled, randomized clinical trial showing a beneficial effect of histamine H2 antagonism on the psychopathology in treatment resistant schizophrenia.  The effect of famotidine was clinically relevant, with reduction of around 10% in symptomatology in the treatment group during the four-week trial and virtually no change in the placebo group.  Our results suggest that a H2 receptor antagonist has antipsychotic properties and may provide a new potential pharmacological approach to the treatment of patients with schizophrenia who have not responded well enough to presently available treatments.  In summary, our study shows that the histamine system in the brain offers a potential drug development target in psychosis. 
